

Amikacin
Essential medicine status
General description

INN
Amikacin
ATC codes
[J01GB06](#)
Medicine type
Chemical agent
Antibiotic groups
[ACCESS](#)
EML status history
First added in 1999 ([TRS 895](#)) for [Multi-drug resistant Mycobacterium tuberculosis](#)
Added in 2017 ([TRS 1006](#)) for [Neutropenia](#)
Changed in 2021 ([TRS 1035](#)) for [Infectious blepharitis](#)
Changed in 2021 ([TRS 1035](#)) for [Other specified conjunctivitis](#)
Added in 2023 ([TRS 1049](#)) for [Acute pyelonephritis](#)
Added in 2023 ([TRS 1049](#)) for [Sepsis without septic shock](#)
Added in 2023 ([TRS 1049](#)) for [Inflammatory and other diseases of prostate](#)
Therapeutic equivalent for
[gentamicin](#) for [Infectious blepharitis](#)
[gentamicin](#) for [Other specified conjunctivitis](#)
Wikipedia
[Amikacin](#)
DrugBank
[Amikacin](#)
Recommendations
Section
Access group antibiotics

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate); 50 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
- Parenteral > General injections > unspecified: 50 mg per mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)

Indications

First choice

[Neutropenia \(high-risk\)](#)

Section
Antituberculosis medicines

- Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)

Indications

[Multi-drug resistant Mycobacterium tuberculosis](#)